Pioneering Treatment for Aortic Regurgitation
Authors:
- 22 December 2025
- journal article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (24) , 3052-3054
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Reply to Garcia-Villarreal et al. concerning the 2025 ESC/EACTS Guidelines for the Management of Valvular Heart DiseaseEuropean Journal of Cardio-Thoracic Surgery, 2025
- Long-Term Outcomes of Patients Requiring Pacemaker Implantation After Transcatheter Aortic Valve ReplacementJACC: Cardiovascular Interventions, 2025
- Aortic regurgitation: from mechanisms to managementEuroIntervention, 2024
- Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm studyThe Lancet, 2024
- Transfemoral transcatheter aortic valve replacement with VitaFlowTM valve for pure native aortic regurgitation in patients with high surgical risk: Rationale and design of a prospective, multicenter, and randomized SEASON-AR trialAmerican Heart Journal, 2024
- Transcatheter Treatment of Native Aortic Valve RegurgitationJACC: Cardiovascular Interventions, 2023
- Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve ImplantationNew England Journal of Medicine, 2020
- Contemporary Presentation and Management of Valvular Heart DiseaseCirculation, 2019
- Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐AnalysisJournal of the American Heart Association, 2017
- Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)The American Journal of Cardiology, 1999